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Increased radiographic progression of distal 
hand osteoarthritis occurring during biologic 
DMARD monotherapy for concomitant 
rheumatoid arthritis
C. A. Lechtenboehmer1†, T. Burkard2†, S. Reichenbach3,4, U. A. Walker5, A. M. Burden2† and T. Hügle6*† 
Abstract 
Objectives: A considerable proportion of patients with rheumatoid arthritis (RA) also suffer from hand osteoarthritis 
(OA). We here assess the association between conventional synthetic (cs) and biological (b) disease-modifying anti-
rheumatic drugs (DMARDs) and radiographic distal interphalangeal-(DIP) OA in patients with RA.
Methods: Adult RA patients from a longitudinal Swiss registry of rheumatic diseases who had ≥ 2 hand radio-
graphs were included at the first radiograph and followed until the outcome or the last radiograph. Patients were 
grouped into two cohorts based on whether DIP OA was present or absent at cohort entry (cohorts 1 and 2, 
respectively). Modified Kellgren-Lawrence scores (KLS) were obtained by evaluating DIP joints for the severity of 
osteophytes, joint space narrowing, subchondral sclerosis, and erosions. KLS ≥ 2 in ≥ 1 DIP joint indicated incident 
or existing OA, and increase of ≥ 1 in KLS in ≥ 1 DIP joint indicated progression in existing DIP OA. Time-varying Cox 
regression and generalized estimating equation (GEE) analyses were performed. We estimated hazard ratios (HRs) 
and odds ratios (ORs) with 95% confidence intervals (CI) of DIP OA incidence (cohort 2), or progression (cohort 1), in 
bDMARD monotherapy, bDMARD/csDMARD combination therapy, and past or never DMARD use, when compared to 
csDMARD use. In post hoc analyses, we descriptively and analytically assessed the individual KLS features in cohort 1.
Results: Among 2234 RA patients with 5928 radiographs, 1340 patients had DIP OA at baseline (cohort 1). Radio-
graphic progression of DIP OA was characterized by new or progressive osteophyte formation (666, 52.4%), joint 
space narrowing (379, 27.5%), subchondral sclerosis (238, 17.8%), or erosions (62, 4.3%). bDMARD monotherapy had 
an increased risk of radiographic DIP OA progression compared to csDMARD monotherapy (adjusted HR 1.34 [95% CI 
1.07–1.69]). The risk was not significant in csDMARD/bDMARD combination users (HR 1.12 [95% CI 0.96–1.31]), absent 
in past DMARD users (HR 0.96 [95% CI 0.66–1.41]), and significantly lower among never DMARD users (HR 0.54 [95% CI 
0.33–0.90]). Osteophyte progression (HR 1.74 [95% CI 1.11–2.74]) was the most significantly increased OA feature with 
bDMARD use compared to csDMARD use. In 894 patients without initial DIP OA (cohort 2), the risk of incident OA did 
not differ between the treatment groups. The results from GEE analyses corroborated all findings.
Conclusions: These real-world RA cohort data indicate that monotherapy with bDMARDs is associated with 
increased radiographic progression of existing DIP OA, but not with incident DIP OA.
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What is already known about this subject?
• There are conflicting data about the benefit of treat-
ment with cs- or bDMARDs for distal hand osteo-
arthritis.
• Direct and indirect osteo-anabolic proper-
ties of DMARDs are known, but the net effect 
on osteophytosis as a hallmark of DIP OA is 
unclear.
What does this study add?
• bDMARD monotherapy enhanced pre-existing 
distal hand osteoarthritis compared to csDMARD 
standard therapy in a predominantly female and 
postmenopausal RA population.
• Growing of osteophytes is the main underlying 
cause of increased radiographic progression occur-
ring under bDMARDs.
• Concomitant osteoporosis or receiving osteoporo-
sis therapy reduced this effect.
How might this impact clinical practice or future 
developments?
• Hand radiographs of RA patients at baseline 
and during follow-up undergoing DMARD 
therapy should be assessed for distal HOA 
lesions.
• In patients with pre-existing DIP OA undergoing 
bDMARD monotherapy, the hands should be mon-
itored radiographically.
Key messages
• Biological DMARD monotherapy potentially 
enhances the risk of progression of pre-existing 
DIP OA in RA patients, mainly through osteophyte 
growth.
• This effect is stronger under non-TNFi bDMARDs 
and in patients under 55 years of age.
• There is no increased incidence of DIP OA with cs- 
or bDMARD therapy in patients with RA.
• Osteoporosis or anti-osteoporotic therapy, but not 
prednisone, diminishes the risk of radiographic DIP 
OA progression under bDMARDs.
Introduction
Hand osteoarthritis (HOA) and rheumatoid arthritis 
(RA) are two distinct entities, which often occur simul-
taneously. Marginal erosions are a radiologic hallmark of 
RA, while HOA is typically characterized by osteophyte 
formation, usually in the distal (DIP) or proximal inter-
phalangeal (PIP) joints [1]. Radiographic progression of 
HOA is a dynamic process. In contrast to marginal ero-
sions, which can be observed in the early stages of RA, 
central erosions in OA usually occur after joint space col-
lapse. In DIP OA, the joint space undergoes radiographic 
reorganization, known as the “repair phase,” a finding 
that typically does not occur in RA joints [2].
Inflammation seems to be a driver of DIP OA. Treat-
ment with prednisone over 6 weeks has been reported 
to effectively reduce pain in inflammatory HOA [3]. 
Moreover, in a cohort of patients with concomitant RA, 
prolonged systemic inflammation with a high erythro-
cyte sedimentation rate (esr) over 3 years was suggested 
to be a risk factor for radiographic DIP OA incidence [4]. 
In contrast, in a previous study, we found no association 
between RA disease activity measured by DAS28-BSR 
(RA disease activity score using 28 joints and esr) and 
radiographic progression of DIP OA [5]. There is a mul-
titude of efficacious RA medications, some of those have 
been studied also in HOA. The use of methotrexate over 
3 months in patients with erosive HOA was associated 
with a significantly increased rate of radiographic trans-
formation from the erosive to the repair phase, indicat-
ing a potential anti-erosive effect of methotrexate in 
HOA [6]. However, data on TNF inhibitors (TNFis) in 
HOA are controversial. Treatment with etanercept or 
adalimumab was associated with increased radiographic 
subchondral remodeling after 12 months and anti-erosive 
effects by TNFi were described in inflammatory DIP OA 
[7, 8]. In another 12-week prospective trial, adalimumab 
had no effect on MRI-detected synovitis or bone marrow 
lesions in HOA [9]. In patients with concomitant RA, inf-
liximab mitigated the progression of HOA in the PIP but 
not in DIP joints [4], potentially because the DIP joints 
are rarely affected by RA. On the other hand, Loef et al. 
described a reduced risk of radiographic progression of 
DIP OA in 143 patients undergoing prolonged TNFi-
methotrexate combination therapy in an RA cohort [10].
The impact of conventional synthetic (cs) or biologi-
cal (b) DMARDs on radiographic HOA as mono- ver-
sus combination therapy has never been studied over 
the long term. This is of interest as DMARDs reduce 
bone resorption and, as consequence, stimulate new 
bone with a potential negative impact on osteophytes. 
Thus, we aimed to assess the association between several 
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DMARDs and DIP OA in RA patients given a 17-year 
study period.
Methods
Study design and data source
We conducted a cohort study using data derived from 
patients in the Swiss Clinical Quality Management in 
Rheumatic Diseases (SCQM) registry. The SCQM regis-
try was established in 1997 and is used to prospectively 
follow RA patients [11]. RA diagnoses are made by board-
certified rheumatologists. Follow-up for the SCQM reg-
istry involves annual physical examination (i.e., tender 
joint count, swollen joint count), disease activity scores 
(e.g., DAS28), laboratory tests (i.e., esr), and radiographs. 
Other relevant health issues such as diagnosis of osteo-
porosis and its treatment are reported by the patient 
and recorded by the rheumatologist into SCQM. Clini-
cal information is usually updated every time a patient 
changes anti-rheumatic therapy but at least once a year 
during a regular visit. Ethical approval for this study was 
obtained from the local ethics committees. All patients 
provided written informed consent.
Study population
We included patients with clinically diagnosed RA who 
had at least two eligible hand radiographs taken between 
January 1997 and October 2014. Radiographs were con-
sidered eligible if all eight DIP joints could be scored. 
Patients entered the study on the date of their first eli-
gible radiograph. Each individual’s observation period 
lasted until the outcome or the final eligible radiograph. 
We divided the study population into two cohorts 
based on whether DIP OA (assessed by modified KLS) 
was present or absent at cohort entry (cohorts 1 and 2, 
respectively).
Exposures
We defined the following mutually exclusive treatment 
groups: csDMARD monotherapy (comparator group 
given the biggest size), bDMARD monotherapy, cs/
bDMARD combination therapy, past use of any DMARD, 
and previously unexposed to DMARD therapy (called 
never-use). csDMARDs included methotrexate, leflu-
nomide, sulfasalazine, and chloroquine. bDMARDs 
included TNFis (e.g., adalimumab, certolizumab, etaner-
cept, infliximab, and golimumab) and non-TNFis (e.g., 
abatacept, tocilizumab and rituximab), by which we 
additionally stratified in cohort 2 given the observed 
increased risks of DIP OA progression of bDMARD 
users. The targeted synthetic DMARD tofacitinib was 
available during the observation period but was not used 
by any of the eligible patients.
The current exposure included 31 days after the end of 
supply. Thus, past users were defined as having been off 
treatment for at least this period.
Exposures of interest were assessed at baseline for time-
invariant analyses and additionally at every other radio-
graph or visit for time-varying analyses. The date of the 
radiographic evaluation and visit date coincided in 88.8% 
of cases, and when we allowed a 1-month time window 
to assign radiographic information to the patient’s visit, 
this number increased to 93.3% (i.e., 6.7% of radiographs 
did not have accompanying visit information). Patient 
visits were recorded in SCQM on an average of once 
per year, and this interval was similar between the treat-
ment groups (Additional file 1: Table S1). In time-varying 
analyses, we accounted for patients changing exposure 
groups during their observation period. Examples of 
exposure evaluation for time-varying analyses can be 
seen in Additional file 1: Figure S1.
Outcome
A trained radiology resident (CAL) blinded to patient 
data assessed conventional postero-anterior hand radio-
graphs from each patient with known time order. The 
reader was trained by a set of 100 radiographs that have 
been evaluated by two senior rheumatologists (TH, 
UAW). As the standard for reading DIP OA, we used the 
Osteoarthritis Research Society International (OARSI) 
atlas [12]. DIP joints were scored for osteophyte severity 
(range 0–3), joint space narrowing (range 0–3), the pres-
ence of subchondral sclerosis, and the presence of central 
erosions, and these evaluations were used to formulate 
the modified KLS (range 0–4) [13].
Following the initial assessment of 7499 hand radio-
graphs from 2870 RA patients, groups of 200 radiographs 
with an average of 60 patients were reassessed until 
Cohen’s κ coefficient, an indicator of intra-rater reliabil-
ity, reached the pre-defined value of κ ≥ 0.70 [14]. This 
value was exceeded after 800 radiographs were assessed. 
The re-evaluated scores were used for the final analysis. 
In the final 200 rescored radiographs, kappa values were 
recorded as follows: K/L grade 0.90, osteophyte sever-
ity 0.77, joint space narrowing 0.83, subchondral scle-
rosis 0.91, and central erosions 0.92. The percentage of 
erosive joint surface destruction (in 19% increments) of 
bilateral metacarpophalangeal (MCP) joints 2–5 (with an 
unknown chronology) was assessed by the SCQM foun-
dation using a similar scoring method to that described 
by Rau et al. In brief, the Ratingen score is based on the 
amount of joint surface destruction of each MCP and PIP 
joint. For this analysis, percentages of erosive joint sur-
face destruction in all 8 MCP joints were summed (range 
0–800%) and categorized. The intra-class correlation 
coefficient was 0.98.
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Our primary outcome, assessed in cohort 1, was OA 
progression defined as an increase of ≥ 1 point in the 
summed KLSs of all eight DIP joints (range 0–32). 
The reliability of change was estimated by the κ value 
of 0.84; the smallest detectable change was a KLS of 
0.13.
Our secondary outcome, assessed in cohort 2, was 
the rate of incident OA defined as a KLS ≥ 2 in ≥ 1 DIP 
joint (K/L grade 1 [i.e., questionable OA] was not rated 
as OA).
Covariates
Based on the literature review, we included the follow-
ing a priori covariates in our adjusted analyses since they 
are confounders or risk factors for incident/progressive 
HOA: age (continuous), sex (binary), body mass index 
(BMI, continuous), RA duration (continuous), rheuma-
toid factor (RF) status (binary), DAS28-esr score (con-
tinuous), prednisone use (binary), cardiac disorders (i.e., 
myocardial infarction, ischemic heart disease, congestive 
heart failure, binary), hypertension (diagnosis or treat-
ment, binary), osteoporosis (diagnosis or treatment, 
binary), hand surgery (binary), or large joint OA or hip/
knee arthroplasty (binary). All variables were assessed at 
each radiograph/visit except for sex and RF status, which 
were given per patient (i.e., their values could not change 
over time).
In time-invariant analyses (baseline model), we per-
formed a sensitivity analysis in which we additionally 
adjusted for the use of csDMARDs for ≥ 1 year prior 
to cohort entry and the use of bDMARDs for ≥ 1 year 
prior to cohort entry to account for prevalent use of 
cs/bDMARDs at cohort entry. This analysis yielded 
slightly higher HRs of DIP OA incidence/progression 
in bDMARD and cs/bDMARD combination therapy 
users than did the overall baseline analysis, data not 
shown.
A total of four variables had missing data (BMI, RA 
duration, RF status, DAS28-esr score). All variables for 
which we aimed to adjust for as well as the exposure and 
the outcome variable were part of the model with which 
we performed the two-level multiple imputation (by 
patient) of the missing values. We used the fully condi-
tional specification imputation method and the Gibbs 
Markov chain Monte Carlo algorithm (because of some 
small clusters) in the BLIMP software 2.2 [15]. Although 
the overall missingness was only around 20%, we imputed 
40 datasets. The imputation model was tested using the 
potential scale reduction (PSR) and performed at a PSR 
of < 1.02 which indicates model convergence. Detailed 
information about data missingness and the multiple 
imputation method can be found in Additional file  1: 
Tables S2–S4.
Statistical analysis
Statistical analyses were performed separately for the two 
cohorts 1 and 2. We described patient characteristics per 
exposure group at cohort entry (i.e., information chang-
ing over time as used in time-varying analyses was not 
described). Using Cox proportional hazard (PH) regres-
sion analysis, we estimated crude and adjusted hazard 
ratios (HRs) and 95% confidence intervals (CI) of DIP OA 
progression (cohort 1) and of incident DIP OA (cohort 
2) using patient information at cohort entry only in all 
exposure groups (i.e., bDMARD, cs/bDMARD combina-
tion, past DMARD use, never DMARD use) when com-
pared to csDMARD use (called baseline model). Cox PH 
assumptions were tested using the Martingale residual 
method and did not hold for csDMARD use or hyperten-
sion in cohort 1, or for never DMARD use in cohort 2. 
Therefore, since exposure and covariates changed over 
time, we additionally used time-varying Cox regression 
analyses. We additionally estimated the crude incidence 
rates as absolute risks based on the numbers of events 
and determined the follow-up times per exposure group. 
To test the model specifications, we chose at random one 
imputed dataset. The lowest Akaike Information Crite-
rion (AIC) was reached with linear terms (i.e., introduc-
tion of interaction terms, quadratic or cubic terms did 
not lower the AIC value). Furthermore, for robustness 
assessment, we repeated our overall time-varying analy-
ses using generalized estimating equation (GEE) analysis. 
Examples of data management for each analysis (Cox PH 
regression analysis, time-varying Cox regression analy-
sis, GEE analysis) can be seen in Additional file 1: Tables 
S5–S7.
In exploratory subgroup analyses, we assessed sub-
groups of age (≤ 55 years, > 55 years) and RF status 
(positive, negative) at cohort entry. Moreover, because of 
their potential influence on bone turnover, we assessed 
subgroups of concomitant osteoporosis and concurrent 
prednisone in time-varying analyses. Since we aimed 
to assess the impact of concomitant prednisone and 
bDMARD use, bDMARD use without prednisone use was 
the comparator in this subgroup analysis.
DAS28-esr may be seen as a mediator variable; there-
fore, we performed a sensitivity analysis without adjust-
ing for it in time-varying Cox regression analyses. 
Furthermore, since the detection of the outcome is only 
possible if a radiograph is taken, in sensitivity analyses 
using time-varying Cox regression, we led the outcome 
by 6 months (183 days).
Given the observed increased risks of DIP OA pro-
gression of bDMARD users, in a post hoc analysis in 
cohort 1, we descriptively and analytically assessed 
the progression of individual KLS components (osteo-
phytes, joint space narrowing, sclerosis, and erosion). 
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Progression of osteophyte and joint space narrowing 
were defined by an increase of ≥ 1 score in ≥ 1 DIP 
(continuous measurement). Sclerosis and erosion were 
measured binary, and progression was defined as an 
increase of ≥ 1 in frequency. In a further post hoc anal-
ysis, we adjusted our Cox regression analyses of DIP OA 
for fewer variables (i.e., age, sex, rheumatoid arthritis 
duration, hypertension, osteoporosis) because some of 
the smaller exposure groups ran the risk of overfitting.
The GEE analyses were performed in Stata/IC 16 
while all other analyses were performed using the SAS 
statistical software version 9.4 (NC, USA).
Results
Baseline characteristics
A total of 8203 RA patients are included in SCQM until 
October 2014. Thereof, 2869 patients had at least 1 radi-
ograph taken. A total of 2234 patients with at least two 
scorable hand radiographs were eligible for this study 
(Fig. 1), and the patients are provided in Additional file 1: 
Table S8.
A total of 1340 patients had DIP OA at baseline and 
were included in the analysis of progression. The major-
ity of patients were receiving csDMARDs (n = 847), 
bDMARDs (n = 72), or combination therapy (n = 257), 
while the remainder had used DMARDs in the past (n = 
19) or were previously unexposed to DMARD therapy 
(n = 145). Every patient had on average 2.7 radiographs 
taken with a median of 3.0 years (interquartile range 
2.0–4.4 years) between two radiographs. The median 
duration between the two radiographs in cohort 1 ranged 
between 2.4 years in never DMARD users and 3.2 years 
in bDMARD users or past DMARD users and was gener-
ally higher in patients in cohort 2 without DIP OA (Addi-
tional file 1: Table S9).
Table  1 presents the patient information at baseline. 
Around 77% of the patients were female, with a slightly 
higher proportion of women in the bDMARD group 
Fig. 1 Flow chart of the study population. DIP, distal interphalangeal; OA, osteoarthritis; SCQM, Swiss Clinical Quality Management in Rheumatic 
Diseases
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(83.3%). The mean age was also similar between the 
exposure groups, ranging from 58 to 61 years. The mean 
duration of follow-up ranged from 2.8 years in past users 
to 4.3 years in never-users. The mean DAS28-esr was 
4.0, with similar standard deviations of around 1.4 in 
patients with csDMARD or bDMARD monotherapy. The 
percentage of patients who used additional prednisone 
was approximately 52% in the csDMARD, bDMARD, 
and past user groups; 57.2% in the combination therapy 
group; and 42.8% in the never-user group. Compared to 
the csDMARD group, the bDMARD group, but not the 
past- and never-user groups, had longer RA disease dura-
tion, higher proportions of rheumatoid factor positivity, 
hypertension, cardiac disorders, and osteoporosis.
Effects of DMARDs on radiographic DIP OA evolution
Among the 1340 patients with radiographic DIP OA at 
cohort entry, time-varying Cox analyses demonstrated 
a significantly higher HR for radiographic DIP OA pro-
gression in patients receiving bDMARD (1.34 [95% 
CI 1.07–1.69]) versus csDMARD monotherapy. Con-
versely, HRs were lower in past DMARD users (HR 0.96 
[95% CI 0.66–1.41]) and never DMARD users (HR 0.54 
[95% CI 0.33–0.90]) [Table 2]. The latter indicates a 46% 
lower risk of DIP OA progression in DMARD-naive RA 
patients compared to the csDMARD group.
CsDMARD/bDMARD combination therapy showed 
no significant difference compared to csDMARD mono-
therapy (1.12 [95% CI 0.96–1.31]). Regarding bDMARD 
monotherapy, the effect size of DIP OA progression was 
higher in the non-TNFi subgroup (2.07 [95% CI 1.35–
3.20]) than in the TNFi subgroup (1.26 [95% CI 0.98–
1.62]), though the number of events in the former group 
was small.
In the explorative subgroup analyses, we observed 
higher effect sizes for radiographic DIP OA progression 
Table 1 Patient characteristics of patients with DIP OA at cohort entry
DIP OA distal interphalangeal joint osteoarthritis, bDMARD biologic disease-modifying antirheumatic drug, BMI body mass index, csDMARD conventional synthetic 
disease-modifying antirheumatic drug, DAS Disease Activity Score, esr erythrocyte sedimentation rate, IQR interquartile range, RA rheumatoid arthritis, RF rheumatoid 
factor, SD standard deviation
a DAS28-esr = (0.56 × √[TJC28] + 0.28 × √[SJC28] + 0.70 × ln[ESR]) × 1.08 + 0.16
b csDMARD use includes methotrexate, leflunomid, sulfasalazin, chloroquine, azathioprine, cyclosporin A, and cyclophosphamid
c bDMARD use includes abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, and tocilizumab
d Prednisone use includes systemic or intra-articular prednisone use
e Cardiac disorders include angina pectoris, myocardial infarction, arrhythmias, ischemic heart failure, angioplasty, or their treatment
f Hypertension includes also anti-hypertensive treatment
g Osteoporosis or fractures include also anti-osteoporotic treatment
h Large joint osteoarthritis includes hip/knee replacements
Patient characteristics at baseline visit csDMARD, n = 847 bDMARD, n = 72 Combination, n = 257 Past-use, n = 19 Never-use, n = 145
Mean age [years] (SD) 60.1 (9.9) 61.9 (10.5) 58.6 (10.6) 60.7 (9.9) 60.9 (10.1)
Female (%) 653 (77.1%) 60 (83.3%) 195 (75.9%) 13 (68.4%) 112 (77.2%)
Mean follow-up time [years] (SD) 3.9 (2.3) 3.4 (1.6) 3.4 (1.9) 2.8 (1.2) 4.3 (2.8)
Mean BMI (SD) 25.9 (4.9) 24.9 (4.0) 25.6 (5.8) 25.6 (2.3) 25.6 (4.5)
Missing (%) 152 (17.9%) 3 (4.2%) 9 (3.4%) 6 (31.6%) 58 (40.0%)
Median RA duration [years] (IQR) 5.3 (2.0–12.8) 11.2 (5.0–18.9) 8.0 (3.9–14.4) 6.5 (2.7–8.7) 6.9 (1.7–16.4)
Missing (%) 21 (2.5%) 3 (4.2%) 8 (3.0%) 1 (5.3%) 7 (4.8%)
RF negative (%) 275 (32.5%) 33 (45.8%) 77 (30.0%) 6 (31.6%) 53 (36.6%)
RF positive (%) 559 (66.0%) 36 (50.0%) 163 (63.4%) 10 (52.6%) 78 (53.8%)
Missing (%) 13 (1.5%) 3 (4.2%) 17 (6.6%) 3 (15.8%) 14 (9.7%)
Mean DAS28-esra (SD) 4.0 (1.5) 4.1 (1.3) 3.9 (1.5) 3.7 (1.8) 4.4 (1.4)
Missing (%) 44 (5.2%) 1 (1.4%) 13 (5.1%) 4 (21.1%) 37 (25.6%)
≥ 365 days of current csDMARD  useb (%) 281 (33.2%) 0 129 (50.2%) 0 0
≥ 365 days of current bDMARD  usec (%) 0 18 (25.0%) 56 (21.8%) 0 0
Prednisone  used (%) 443 (52.3%) 37 (51.4%) 147 (57.2%) 10 (52.6%) 62 (42.8%)
Cardiac  disorderse (%) 80 (9.5%) 12 (16.7%) 25 (9.7%) 7 (36.8%) 10 (6.9%)
Hypertensionf (%) 206 (24.3%) 27 (37.5%) 52 (20.2%) 4 (21.1%) 37 (25.5%)
Osteoporosis or  fractureg (%) 106 (12.5%) 27 (37.5%) 76 (29.6%) 1 (5.3%) 16 (11.0%)
Large joint  osteoarthritish (%) 82 (9.7%) 9 (12.5%) 45 (17.5%) 5 (26.3%) 17 (11.7%)
Hand surgery (%) 67 (7.9%) 15 (20.8%) 33 (12.8%) 1 (5.3%) 12 (8.3%)
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under bDMARD therapy in patients ≤ 55 years (1.49 
[95% CI 1.01–2.21]) than in those > 55 years (1.21 [95% 
CI 0.90–1.61]) [Table  3]. In both the csDMARD and 
bDMARD monotherapy groups, there was a lower risk 
of DIP OA progression in patients with concomitant 
osteoporosis, or osteoporosis therapy, than in those 
without. Conversely, neither rheumatoid factor posi-
tivity nor prednisone therapy was associated with DIP 
OA progression under either bDMARD or combination 
therapy.
Table 4 presents the post hoc analyses of the KLS com-
ponents. We observed that 52.4% (666 progressions) of 
patients progressed in terms of new osteophyte forma-
tion, 27.5% (379 progressions) in joint space narrowing, 
17.8% (238 progressions) in sclerosis, and 4.3% in ero-
sion (62 progressions). The time-varying Cox regression 
analysis yielded the highest HRs of osteophyte progres-
sion (1.74 [95% CI 1.11–2.74]), joint space narrowing 
(1.38 [95%CI 1.01–1.86]) in bDMARD users compared 
to csDMARD users. Conversely, the HR for erosions 
was not statistically significant (1.51 [95%CI 0.76–3.00]). 
Additional file 1: Table S10 presents the post hoc analy-
ses when adjusting the Cox regression analyses of DIP 
OA progression for fewer variables; the results remained 
unchanged.
Incidence of osteoarthritis
A total of 894 patients without radiographic DIP OA at 
baseline were included in cohort 2. They were less likely to 
be female than those with OA. Patients without OA in the 
bDMARD group had lower mean BMI values than those 
in the csDMARD, combination, past user, and never-user 
groups (Additional file 1: Table S11). Proportions of rheuma-
toid factor positivity were around 30% in both the csDMARD 
and bDMARD groups. In time-varying Cox regression analy-
sis, the incidence of DIP OA was not higher in the bDMARD 
group than in the csDMARD group (0.89 [95% CI 0.56–1.43]) 
(Table 5). In a subgroup analysis, neither osteoporosis nor 
prednisone therapy was associated with the incidence of 
radiographic DIP OA (Additional file 1: Table S12).
Sensitivity analyses
Values of HRs of progression of DIP OA in bDMARD 
users compared to csDMARD users remained 
unchanged when not adjusting for DAS28-esr (1.35 
[95% CI 1.07–1.70]) and slightly attenuated when lead-
ing the outcome by 6 months (1.24 [95% CI 0.97–1.59]) 
(Additional file  1: Tables S13–S14). HRs of incident 
DIP OA remained largely unchanged in sensitivity 
analyses when not adjusting for DAS28-esr or when 
leading the outcome by 6 months (Additional file  1: 
Tables S15–S16).
Table 2 Incidence rates, hazard ratios, and odds ratios of hand OA progression per treatment group following Cox regression analysis 
and GEE analysis among those with distal interphalangeal osteoarthritis at baseline (N = 1340)
bDMARD biologic disease-modifying antirheumatic drug, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, IR incidence 
rate, HR hazard ratio, OA osteoarthritis, OR odds ratio, TNFi tumor necrosis factor inhibitor
a Adjusted for age, sex (time-invariant), body mass index, rheumatoid arthritis duration, rheumatoid factor (time-invariant), DAS28-esr score, prednisone use, cardiac 
disorders, hypertension, osteoporosis, hand surgery, large joint osteoarthritis, or hip/knee arthroplasty






IR per 1000 
person-
years
Crude HR (95% CI) Adjusted HR (95% 
CI)a
Crude OR (95% CI) Adjusted OR (95% 
CI)a
Analysis using baseline information only
 csDMARD 526 3306.0 159.1 Ref (1.00) Ref (1.00) NA NA
 bDMARD 34 244.7 138.9 0.96 (0.71–1.31) 1.07 (0.78–1.46) NA NA
 Combination 132 886.6 148.9 1.03 (0.85–1.24) 1.09 (0.89–1.32) NA NA
 Past-use 8 53.8 148.7 1.24 (0.70–2.19) 1.15 (0.60–2.20) NA NA
 Never-use 83 629.7 131.8 0.77 (0.61–0.97) 0.81 (0.63–1.02) NA NA
Time-varying analysis
 csDMARD 421 2885.7 145.9 Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00)
 bDMARD 79 391.9 201.6 1.23 (0.98–1.54) 1.34 (1.07–1.69) 1.49 (1.15–1.93) 1.53 (1.17–2.00)
  TNFi 67 357.6 187.4 1.16 (0.91–1.48) 1.26 (0.98–1.62) 1.36 (1.03–1.79) 1.41 (1.06–1.88)
  Non-TNFi 12 34.3 349.9 1.85 (1.18–2.89) 2.07 (1.35–3.20) 2.94 (1.50–5.77) 2.79 (1.41–5.52)
 Combination 236 1378.7 171.2 1.05 (0.90–1.22) 1.12 (0.96–1.31) 1.12 (0.95–1.33) 1.16 (0.97–1.38)
  TNFi 210 1293.7 162.3 1.01 (0.86–1.18) 1.09 (0.92–1.28) 1.07 (0.90–1.28) 1.11 (0.93–1.33)
  Non-TNFi 26 85 305.9 1.54 (1.10–2.15) 1.56 (1.10–2.23) 1.75 (1.13–2.73) 1.77 (1.13–2.77)
 Past-use 24 128.4 186.9 0.96 (0.64–1.42) 0.96 (0.66–1.41) 1.36 (0.87–2.14) 1.30 (0.83–2.05)
 Never-use 23 335.9 68.5 0.51 (0.31–0.83) 0.54 (0.33–0.90) 0.89 (0.57–1.38) 0.91 (0.58–1.42)
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Table 3 Hazard ratios of hand OA progression per treatment group following time-varying Cox regression analyses in subgroups 
based on age, rheumatoid factor, osteoporosis (treatment), and prednisone use
bDMARD biologic disease-modifying antirheumatic drug, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, HR hazard 
ratio
a Adjusted for age, sex (time-invariant), body mass index, rheumatoid arthritis duration, rheumatoid factor (time-invariant), DAS28-esr score, prednisone use, cardiac 
disorders, hypertension, osteoporosis, hand surgery, large-joint osteoarthritis, or hip/knee arthroplasty




Crude HR (95% CI) Adjusted HR (95% CI)a
Age ≤ 55 years at cohort entry
 csDMARD 130 860.6 Ref (1.00) Ref (1.00)
 bDMARD 31 127.4 1.36 (0.93–2.00) 1.49 (1.01–2.21)
 Combination 87 526.8 0.94 (0.73–1.22) 1.01 (0.78–1.33)
 Past-use 10 39.2 0.96 (0.41–2.26) 1.09 (0.51–2.34)
 Never-use 6 111.3 0.34 (0.14–0.80) 0.34 (0.14–0.84)
Age > 55 years at cohort entry
 csDMARD 291 2025.1 Ref (1.00) Ref (1.00)
 bDMARD 48 264.6 1.13 (0.86–1.51) 1.21 (0.90–1.61)
 Combination 149 851.9 1.11 (0.92–1.33) 1.16 (0.96–1.41)
 Past-use 14 89.2 0.84 (0.52–1.36) 0.79 (0.48–1.29)
 Never-use 17 224.6 0.62 (0.35–1.10) 0.68 (0.37–1.25)
Rheumatoid factor negative at cohort entry
 csDMARD 132 1014.4 Ref (1.00) Ref (1.00)
 bDMARD 28 167.5 1.22 (0.83–1.80) 1.33 (0.90–1.96)
 Combination 83 503.8 1.11 (0.85–1.44) 1.21 (0.92–1.58)
 Past-use 7 35.3 1.21 (0.61–2.38) 1.16 (0.58–2.33)
 Never-use 6 126.8 0.42 (0.19–0.92) 0.45 (0.20–1.03)
Rheumatoid factor positive at cohort entry
 csDMARD 284 1832.4 Ref (1.00) Ref (1.00)
 bDMARD 45 210.7 1.20 (0.89–1.60) 1.40 (1.04–1.89)
 Combination 139 809.4 0.99 (0.82–1.21) 1.09 (0.89–1.32)
 Past-use 17 86.6 0.87 (0.52–1.42) 0.86 (0.55–1.36)
 Never-use 16 186.2 0.58 (0.31–1.10) 0.59 (0.31–1.13)
Osteoporosis/fracture or osteoporosis treatment (additionally time-varying)
 csDMARD without osteoporosis 334 2342.2 Ref (1.00) Ref (1.00)
 csDMARD with osteoporosis 87 543.5 0.88 (0.69–1.13) 0.87 (0.68–1.11)
 bDMARD without osteoporosis 50 226.5 1.35 (1.04–1.77) 1.43 (1.09–1.88)
 bDMARD with osteoporosis 29 165.4 1.00 (0.70–1.43) 1.04 (0.72–1.49)
 Combination therapy without osteoporosis 165 952.5 1.06 (0.89–1.27) 1.13 (0.94–1.35)
 Combination therapy with osteoporosis 71 426.2 0.94 (0.75–1.18) 0.95 (0.76–1.20)
 Never/past-use without osteoporosis 38 390.3 0.65 (0.44–0.95) 0.69 (0.47–1.02)
 Never/past-use with osteoporosis 9 74.0 0.68 (0.34–1.37) 0.66 (0.34–1.29)
Prednisone treatment (additionally time-varying)
 csDMARD without prednisone 219 1509.1 0.79 (0.57–1.08) 0.72 (0.52–1.00)
 csDMARD with prednisone 202 1376.6 0.87 (0.64–1.20) 0.81 (0.59–1.12)
 bDMARD without prednisone 38 183.8 Ref (1.00) Ref (1.00)
 bDMARD with prednisone 41 208.2 1.03 (0.69–1.54) 1.07 (0.72–1.60)
 Combination therapy without prednisone 128 679.8 0.90 (0.64–1.25) 0.88 (0.63–1.22)
 Combination therapy with prednisone 108 699.0 0.83 (0.60–1.17) 0.83 (0.59–1.17)
 Never/past-use without prednisone 22 287.8 0.39 (0.23–0.67) 0.36 (0.21–0.63)
 Never/past-use with prednisone 25 176.5 0.90 (0.54–1.47) 0.87 (0.53–1.45)
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Discussion
In this cohort study, among 2234 RA patients with at 
least two hand radiographs, followed for around 4 years, 
1340 patients had radiographic DIP OA at baseline, and 
we observed a 34% increased risk of radiographic pro-
gression associated with bDMARD monotherapy. More 
specifically, this finding was mainly characterized by 
increased new bone formation. Among the 894 patients 
Table 4 Hazard ratios of progression in osteoarthritis components (osteophytes, joint space narrowing, sclerosis, and erosions) per 
treatment group in time-varying Cox regression analysis
bDMARD biologic disease-modifying antirheumatic drug, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, IR incidence 
rate, HR hazard ratio, OA osteoarthritis, OR odds ratio, TNFi tumor necrosis factor inhibitor, JSN joint space narrowing
a Adjusted for age, sex (time-invariant), body mass index, rheumatoid arthritis duration, rheumatoid factor (time-invariant), DAS28-esr score, prednisone use, cardiac 
disorders, hypertension, osteoporosis, hand surgery, large joint osteoarthritis, or hip/knee arthroplasty
b NA: less than 5 outcomes not applicable for result estimation
Exposure Osteophyte progression events Person-time [years] Crude HR (95% CI) Adjusted HR (95% CI)a
 csDMARD 404 2883.3 Ref (1.00) Ref (1.00)
 bDMARD 77 400.3 1.56 (0.90–2.47) 1.74 (1.11–2.74)
  TNFi 66 362.7 1.16 (0.90–1.48) 1.25 (0.97–1.62)
  Non-TNFi 11 37.3 1.60 (1.01–2.53) 1.82 (1.15–2.87)
 Combination 226 1424.9 0.96 (0.82–1.13) 1.02 (0.87–1.20)
  TNFi 203 1321.9 0.98 (0.83–1.16) 1.06 (0.90–1.25)
  Non-TNFi 23 103 1.08 (0.73–1.61) 1.16 (0.78–1.71)
 Past-use 23 131.5 0.90 (0.61–1.35) 0.91 (0.61–1.36)
 Never-use 18 337.5 0.40 (0.23–0.68) 0.41 (0.23–0.72)
Exposure JSN progression events Person-time [years] Crude HR (95% CI) Adjusted HR (95% CI)a
 csDMARD 231 3239.2 Ref (1.00) Ref (1.00)
 bDMARD 51 458.1 1.80 (0.92–3.49) 1.38 (1.01–1.86)
  TNFi 43 410.4 1.33 (0.97–1.82) 1.32 (0.95–1.83)
  Non-TNFi 8 47.4 1.88 (0.96–3.66) 1.76 (0.89–3.46)
 Combination 136 1636.7 0.98 (0.79–1.20) 1.04 (0.83–1.29)
  TNFi 124 1531 1.02 (0.82–1.27) 1.03 (0.82–1.29)
  Non-TNFi 12 105.8 1.15 (0.67–1.98) 1.12 (0.65–1.94)
 Past-use 16 145.8 1.15 (0.72–1.83) 1.19 (0.74–1.92)
 Never-use 15 343.6 0.71 (0.40–1.27) 0.83 (0.46–1.48)
Exposure Sclerosis progression events Person-time [years] Crude HR (95% CI) Adjusted HR (95% CI)a
 csDMARD 160 3302.2 Ref (1.00) Ref (1.00)
 bDMARD 27 484.1 1.66 (0.77–3.57) 1.07 (0.72–1.60)
  TNFi 22 432.3 0.95 (0.61–1.46) 0.97 (0.63–1.52)
  Non-TNFi 5 51.8 1.67 (0.77–3.60) 1.89 (0.87–4.11)
 Combination 84 1673.7 0.90 (0.69–1.17) 0.97 (0.74–1.27)
  TNFi 75 1554.2 0.90 (0.69–1.18) 0.94 (0.71–1.24)
  Non-TNFi 9 119.5 1.28 (0.67–2.45) 1.34 (0.71–2.52)
 Past-use 10 159.5 1.02 (0.53–1.94) 1.04 (0.53–2.01)
 Never-use 9 344.7 0.67 (0.34–1.35) 0.71 (0.35–1.45)
Exposure Erosion progression Person-time [years] Crude HR (95% CI) Adjusted HR (95% CI)a
 csDMARD 41 3571.5 Ref (1.00) Ref (1.00)
 bDMARD 12 542.5 2.77 (0.79–9.70) 1.51 (0.76–3.00)
  TNFi 9 481.1 1.46 (0.71–3.00) 1.32 (0.62–2.80)
  Non-TNFi NAb NAb NAb NAb
 Combination 19 1857.3 0.72 (0.42–1.25) 0.78 (0.43–1.40)
  TNFi 17 1717.3 0.76 (0.43–1.34) 0.76 (0.41–1.39)
  Non-TNFi NAb NAb NAb NAb
 Past-use 6 182.7 2.35 (1.05–5.26) 2.40 (1.04–5.56)
 Never-use NAb NAb NAb NAb
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without DIP OA at baseline, we observed that the risk of 
incident radiographic OA did not differ between those 
receiving csDMARDs or bDMARDs, either in mono- or 
combination therapy.
This is a comprehensive analysis of both incident and 
pre-existing radiographic DIP OA including individual 
KLS components (i.e., osteophytes, joint space narrow-
ing, sclerosis, and erosions) in a well-characterized RA 
patient registry database. We assessed the outcomes 
in both time-invariant and time-varying analyses, we 
adjusted for an extensive set of covariates to mini-
mize residual confounding, and we conducted several 
sensitivity analyses to demonstrate the robustness of 
our findings. Furthermore, we used two-level multiple 
imputation to limit confounding by missingness. How-
ever, despite the strengths of this study, we must inter-
pret our findings in light of several limitations. First, 
bDMARD monotherapy, the group of interest, was 
small and may be subject to selection bias as bDMARD 
monotherapy is not the preferred administration but cs/
bDMARD combination therapy. In a previous study of 
the SCQM registry, initial bDMARD monotherapy was 
more often prescribed to more complex cases with older 
RA patients and higher rates of co-morbidity [16]. Simi-
lar results were obtained in our study where bDMARD 
users had the longest disease duration, highest age, and 
proportions of women and of patients with hyperten-
sion, all of them being risk factors to develop DIP OA 
[17]. While we did control our study population for 
aforementioned covariates, residual confounding may 
remain. Second, groups were not controlled for calen-
dar time which may have resulted in time trend biases 
given a study period of 17 years. However, we controlled 
our analyses for factors which influence treatment 
choice (e.g., RA disease activity), and bDMARDs were 
available throughout the study period. Third, DAS28-esr 
scores at baseline in all exposure groups were relatively 
high; thus, our results might not be generalizable to 
RA patients in remission or low disease activity. Poten-
tially, the high activity scores can be explained by a large 
enrollment of patients at the start of DMARD therapy 
courses and more radiographs being performed early in 
the ultrasound and pre-treat to target era. Fourth, since 
the outcomes could only be assessed when radiographs 
were taken, we likely missed the exact onset of DIP OA 
or DIP OA progression. However, DIP OA evolvement 
and progression is a slow progress, and in a sensitivity 
analysis when leading the outcome by 6 months, the 
results remained largely unchanged for incident DIP 
OA but were slightly attenuated in bDMARD users 
for DIP OA progression which may reveal residual 
confounding in this analysis but may also be due to 
decreased sample size. Unfortunately, information on 
DIP OA symptoms or joint function was not available, 
and the sample size did not allow for stratification by 
DIP OA severity at cohort entry DIP. Furthermore, we 
noted that patients at their first-hand radiographs dif-
fered from all RA patients identified in SCQM at their 
first visit with regard to higher proportions of DMARDs 
use, but a lower proportion of cardiac disorders, large 
Table 5 Incidence rates, hazard ratios, and odds ratios of incident hand OA per treatment group following Cox regression analysis and 
GEE analysis among those without distal interphalangeal osteoarthritis at baseline (N = 894)
bDMARD biologic disease-modifying antirheumatic drug, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, IR incidence 
rate, HR hazard ratio
a Adjusted for age, sex (time-invariant), body mass index, rheumatoid arthritis duration, rheumatoid factor (time-invariant), DAS28-esr score, prednisone use, cardiac 







IR per 1000 
person-
years
Crude HR (95% CI) Adjusted HR (95% 
CI) a
Crude OR (95% CI) Adjusted OR (95% 
CI)a
Analysis using baseline information only
 csDMARD 119 2239.0 53.1 Ref (1.00) Ref (1.00) NA NA
 bDMARD 10 147.2 67.9 1.44 (0.77–2.67) 1.41 (0.75–2.65) NA NA
 Combination 43 750.6 57.3 1.13 (0.80–1.60) 1.09 (0.75–1.58) NA NA
 Past-use 4 55.2 72.5 1.40 (0.54–3.61) 1.85 (0.73–4.66) NA NA
 Never-use 22 793.1 27.7 0.52 (0.33–0.84) 0.59 (0.36–0.97) NA NA
Time-varying analysis
 csDMARD 96 1952.7 49.2 Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00)
 bDMARD 20 377.6 53 0.94 (0.59–1.50) 0.89 (0.56–1.43) 1.14 (0.70–1.87) 1.05 (0.63–1.75)
 Combination 68 1212.7 56.1 1.06 (0.78–1.44) 1.07 (0.78–1.46) 1.08 (0.79–1.49) 1.04 (0.75–1.44)
 Past-use 7 111.4 62.8 1.06 (0.51–2.19) 1.08 (0.50–2.33) 1.51 (0.68–3.32) 1.46 (0.66–3.25)
 Never-use 7 330.7 21.2 0.55 (0.26–1.19) 0.72 (0.32–1.61) 0.92 (0.42–2.01) 1.05 (0.47–2.33)
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joint OA, and previous hand surgery, and longer RA 
duration. Thus, our results may not be generalizable to 
the general RA population. Finally, the fact that radio-
graphic scoring was performed by a single reader can be 
interpreted as a further weakness of this study.
The observed increased risk of DIP OA progression 
in bDMARD users was unexpected as previous trials 
investigating bDMARD monotherapy for the treatment 
of HOA (without RA) revealed either no or a small posi-
tive impact on structural progression [7, 9]. However, 
those studies only assessed smaller sample sizes ver-
sus non-use during a maximal 1-year follow-up, with-
out analyzing individual KLS components. Our results 
are partially in contrast to the results of Loef et al. who 
showed that TNF-csDMARD combination was associ-
ated with reduced radiographic DIP OA progression up 
to 10 years follow-up in patients with concomitant RA 
[10]. A reduced incidence of DIP OA was also observed 
in RA patients under infliximab-csDMARD combination 
therapy but has never been studied for bDMARD mono-
therapy [4].
We postulate that the anti-erosive effects of 
bDMARDs, achieved by reducing osteoclastogenesis 
and the production of RANK ligand, are outweighed by 
these drugs’ known bone anabolic effects, for instance, 
the antagonism of Dkk-1, which finally can lead to 
increased osteophytosis [18]. This hypothesis is sup-
ported by the finding that osteophyte growth was the 
leading radiographic feature of increased progression 
under bDMARDs. We speculate that methotrexate has 
a more pleiotropic effect on other cell types, including 
osteoblasts, thus limiting the pro-osteogenic effects 
of bDMARDs on existing osteophytes [19]. Further-
more, our results suggest that bDMARD monotherapy 
is not restricted to the progression of osteophytes but 
also to joint space narrowing and potentially erosions 
(in small sample size). Clearly, central erosions in DIP 
OA are associated with joint space remodeling and dif-
fer from marginal erosions occurring in RA. Potentially, 
this finding is in line with the description of increased 
transition from the erosive into the remodeling phase 
under methotrexate therapy [6]. The hypothesis of a 
detrimental pro-osteogenic effect of DMARDs is sup-
ported to some extent by the finding that methotrex-
ate and TNFi increase bone density in RA patients but 
do not reduce pathological new bone formation in with 
psoriatic arthritis and not or only discretely in spondy-
larthritis [20, 21].
Finally, our results suggest that concomitant osteo-
porosis and/or osteoporosis treatment reduced the 
progression of DIP OA. In the literature, lumbar bone 
mineral density is positively correlated with osteophyto-
sis and subchondral sclerosis in hand OA but negatively 
with joint space narrowing or erosions [22]. Indeed, 
smaller previous studies have shown positive treatment 
effects of bisphosphonates such as clodronate on pain 
in hand OA [23]. However, the current literature is lim-
ited; therefore, we can only speculate if low bone density, 
or anti-osteoporosis therapy (e.g., bisphosphonates), is 
protective.
These results raise awareness of possible radiographic 
worsening of DIP OA in RA patients, especially those 
receiving bDMARD monotherapy. A baseline radiograph 
of the hand is therefore important to assess and moni-
tor for RA lesions, but also for DIP OA. Ideally, a pro-
spective study is needed to make recommendations for 
bDMARDs for RA patients suffering from radiographic 
of DIP OA.
Conclusion
Biological DMARD monotherapy potentially enhances 
the risk of progression of pre-existing DIP OA in RA 
patients mainly as a result of increased osteophyte 
growth. Direct or indirect osteo-anabolic properties of 
targeted bDMARD therapy might be responsible for 
this observation, at least in this cohort of predominantly 
female and postmenopausal RA patients. Hand radio-
graphs of RA patients at baseline should be assessed for 
distal HOA lesions. In patients with pre-existing DIP OA 
undergoing bDMARD monotherapy, hands should be 
monitored radiographically.
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